Benitec Biopharma Ltd (BNTC) just unveiled an update.
Benitec Biopharma Inc. has awarded its CEO, Dr. Jerel Banks, and Executive Director, Megan Boston, significant stock options as part of their compensation plan. Banks received options for 466,554 shares, while Boston received 200,004 shares, both at a strike price of $5.21, matching the stock’s closing price on the grant date. These options will vest over three years, provided they remain with the company, and will fully vest immediately if the company undergoes a change of control.
See more insights into BNTC stock on TipRanks’ Stock Analysis page.
